Adzynma Wins FDA Approval as First Treatment for Ultra-Rare Blood Clotting Disorder cTTP
XTalks
NOVEMBER 10, 2023
Treatments for cTTP includes prophylactic plasma-based therapy for individuals with chronic disease to reduce the risk of clotting/bleeding by restoring the low amounts or absence of the ADAMTS13 enzyme. For prophylactic ERT, Adyznma is given to help reduce the risk of disease symptoms. “As
Let's personalize your content